+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Cell Therapy - Global Strategic Business Report

  • PDF Icon

    Report

  • 263 Pages
  • September 2024
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 5309390
The global market for Cell Therapy was estimated at US$16.8 Billion in 2023 and is projected to reach US$42.5 Billion by 2030, growing at a CAGR of 14.1% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

Global Cell Therapy Market - Key Trends and Drivers Summarized

What Makes Cell Therapy a Game-Changer in Modern Medicine?

Cell therapy is dramatically reshaping the medical field by using the body's own cells to treat and repair damaged tissues, providing innovative solutions for a wide array of diseases, including cancer, autoimmune disorders, and degenerative conditions. Unlike traditional treatments that often focus on managing symptoms, cell therapy aims to address the root cause of diseases by harnessing living cells that can be engineered or harvested to target specific biological mechanisms. For instance, CAR-T cell therapy has been a breakthrough in oncology, where a patient's T cells are genetically engineered to seek out and destroy cancer cells. This form of therapy has already shown remarkable success in treating certain types of blood cancers and is expanding into other cancer types. In regenerative medicine, stem cell therapy is being used to repair tissues damaged by heart disease, neurodegenerative disorders, and diabetes. These therapies represent a significant leap forward in personalized treatment, offering hope for patients with diseases that were once considered untreatable. As research progresses, cell therapy is becoming a central pillar in the future of personalized medicine, offering tailored treatments that align with a patient's unique genetic and cellular makeup.

How Is Cell Therapy Changing the Way Complex Diseases Are Treated?

Cell therapy is crucial for treating complex diseases that do not respond well to traditional treatments, offering new avenues for therapeutic intervention. In the field of oncology, cell-based treatments like CAR-T therapy have revolutionized cancer treatment by using a patient's own immune cells to target and kill cancerous cells. This highly personalized approach to therapy has shown great success in treating cancers such as leukemia and lymphoma, especially in patients who have not responded to conventional chemotherapy or radiation. Beyond oncology, cell therapy is making strides in managing autoimmune diseases like multiple sclerosis and rheumatoid arthritis, where it helps to modulate and reprogram the immune system, reducing harmful inflammatory responses. In regenerative medicine, stem cell therapies are being developed to restore function to damaged tissues, offering potential cures for conditions like heart failure, spinal cord injuries, and neurodegenerative diseases. These therapies not only aim to repair tissues but also to provide long-term, possibly permanent, solutions by addressing the underlying cellular deficiencies that cause disease. Cell therapy's ability to replace or restore damaged tissues at a cellular level, rather than merely treating symptoms, makes it a game-changer for complex, chronic, and previously untreatable diseases.

How Are Technological Advances Driving Innovation in Cell Therapy?

Technological advancements are rapidly accelerating progress in cell therapy, making it more effective, scalable, and accessible for a variety of diseases. One of the most transformative technologies has been gene editing, particularly with CRISPR-Cas9, which allows for precise modifications of cells to enhance their therapeutic potential. This has revolutionized CAR-T therapies, enabling scientists to engineer T cells that are highly effective at targeting specific cancer cells, while reducing potential side effects. Beyond genetic engineering, advancements in bioprocessing and automation are making it possible to produce large quantities of therapeutic cells in a controlled environment, which is critical as these therapies move from clinical trials to wider market availability. Additionally, improvements in cryopreservation have made it easier to store and transport therapeutic cells, maintaining their viability across long distances and extended periods, which has helped expand the reach of these treatments to more regions globally. Furthermore, artificial intelligence (AI) and machine learning are being integrated into cell therapy development, helping to optimize the manufacturing process, predict patient responses, and improve treatment outcomes. These technological breakthroughs are not only enhancing the precision and efficiency of cell therapies but are also broadening their applications to treat a wider range of diseases, from rare genetic disorders to age-related conditions.

What Factors Are Propelling the Growth of the Cell Therapy Market?

The growth in the cell therapy market is driven by several factors, including the increasing prevalence of chronic and complex diseases, technological advancements, and the rising demand for personalized treatments. One of the most significant drivers is the success of therapies like CAR-T in cancer treatment, which has demonstrated the immense potential of cell therapies to provide durable and effective responses in patients who have exhausted other treatment options. This has led to a surge in investment and research aimed at expanding cell therapy applications to other types of cancer, autoimmune diseases, and genetic disorders. Technological advancements, particularly in gene editing and biomanufacturing, are making it easier to develop and scale these therapies, driving down costs and improving access. The field of regenerative medicine is another major contributor, as therapies using stem cells are increasingly being developed to treat diseases such as heart failure, diabetes, and neurodegenerative disorders, further fueling market growth. Additionally, the growing focus on personalized medicine is spurring demand for cell therapies that can be tailored to individual patients, offering more targeted and effective treatment options. This trend is reinforced by increasing consumer awareness and the desire for advanced, cutting-edge therapies that go beyond traditional pharmaceutical approaches. Regulatory support, including faster approval pathways for breakthrough therapies, is also encouraging the development and adoption of cell-based treatments. With continuous advancements in research, manufacturing capabilities, and regulatory frameworks, the cell therapy market is poised for sustained growth in the coming years, offering transformative treatment options for a wide range of diseases.

Key Insights:

  • Market Growth: Understand the significant growth trajectory of the Research Application segment, which is expected to reach US$31.2 Billion by 2030 with a CAGR of a 14.7%. The Clinical Application segment is also set to grow at 12.6% CAGR over the analysis period.
  • Regional Analysis: Gain insights into the U.S. market, which was estimated at $4.6 Billion in 2023, and China, forecasted to grow at an impressive 13.1% CAGR to reach $6.4 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

  • Detailed Market Analysis: Access a thorough analysis of the Global Cell Therapy Market, covering all major geographic regions and market segments.
  • Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
  • Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Cell Therapy Market.
  • Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

  • How is the Global Cell Therapy Market expected to evolve by 2030?
  • What are the main drivers and restraints affecting the market?
  • Which market segments will grow the most over the forecast period?
  • How will market shares for different regions and segments change by 2030?
  • Who are the leading players in the market, and what are their prospects?

Report Features:

  • Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
  • In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
  • Company Profiles: Coverage of major players such as Anterogen Co., Ltd., Celgene Corporation, Cells for Cells S.A. (C4C), and more.
  • Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Select Competitors (Total 183 Featured):

  • Anterogen Co., Ltd.
  • Celgene Corporation
  • Cells for Cells S.A. (C4C)
  • Fibrocell Science, Inc.
  • GlaxoSmithKline PLC
  • JCR Pharmaceuticals Co., Ltd.
  • Kolon TissueGene, Inc.
  • Medipost Co., Ltd.
  • Novartis AG
  • NuVasive, Inc.
  • Osiris Therapeutics, Inc.
  • Pharmicell Co., Ltd.
  • Stemedica Cell Technologies, Inc.
  • Vericel Corporation

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • Global Economic Update
  • Cell Therapy - Global Key Competitors Percentage Market Share in 2024 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
  • Advancements in Genetic Engineering Propel Growth of Personalized Cell Therapies
  • Rising Incidence of Chronic Diseases Expands Addressable Market for Cell Therapy
  • Increasing Focus on Regenerative Medicine Strengthens Business Case for Stem Cell Therapies
  • Favorable Regulatory Approvals Accelerate Demand for CAR-T Cell Therapies
  • Expanding Clinical Applications of Cell Therapy Spurs Growth in Cancer Treatment Segments
  • Advances in CRISPR Technology Throws the Spotlight on Gene-Edited Cell Therapies
  • Shift Toward Allogeneic Therapies Expands Market Accessibility and Reduces Costs
  • Rising Awareness of the Benefits of Cell-Based Immunotherapies Drives Patient Demand
  • Innovations in Cryopreservation Strengthen Supply Chain and Logistics for Cell Therapies
4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Cell Therapy Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
  • Table 2: World Recent Past, Current & Future Analysis for Cell Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 3: World Historic Review for Cell Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 4: World 16-Year Perspective for Cell Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
  • Table 5: World Recent Past, Current & Future Analysis for Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 6: World Historic Review for Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 7: World 16-Year Perspective for Research by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • Table 8: World Recent Past, Current & Future Analysis for Clinical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 9: World Historic Review for Clinical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 10: World 16-Year Perspective for Clinical by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • Table 11: World Recent Past, Current & Future Analysis for Allogenic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 12: World Historic Review for Allogenic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 13: World 16-Year Perspective for Allogenic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • Table 14: World Recent Past, Current & Future Analysis for Autologous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 15: World Historic Review for Autologous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 16: World 16-Year Perspective for Autologous by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
III. MARKET ANALYSIS
UNITED STATES
  • Cell Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
  • Table 17: USA Recent Past, Current & Future Analysis for Cell Therapy by Application - Research and Clinical - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 18: USA Historic Review for Cell Therapy by Application - Research and Clinical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 19: USA 16-Year Perspective for Cell Therapy by Application - Percentage Breakdown of Value Sales for Research and Clinical for the Years 2014, 2024 & 2030
  • Table 20: USA Recent Past, Current & Future Analysis for Cell Therapy by Therapy - Allogenic and Autologous - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 21: USA Historic Review for Cell Therapy by Therapy - Allogenic and Autologous Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 22: USA 16-Year Perspective for Cell Therapy by Therapy - Percentage Breakdown of Value Sales for Allogenic and Autologous for the Years 2014, 2024 & 2030
CANADA
  • Table 23: Canada Recent Past, Current & Future Analysis for Cell Therapy by Application - Research and Clinical - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 24: Canada Historic Review for Cell Therapy by Application - Research and Clinical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 25: Canada 16-Year Perspective for Cell Therapy by Application - Percentage Breakdown of Value Sales for Research and Clinical for the Years 2014, 2024 & 2030
  • Table 26: Canada Recent Past, Current & Future Analysis for Cell Therapy by Therapy - Allogenic and Autologous - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 27: Canada Historic Review for Cell Therapy by Therapy - Allogenic and Autologous Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 28: Canada 16-Year Perspective for Cell Therapy by Therapy - Percentage Breakdown of Value Sales for Allogenic and Autologous for the Years 2014, 2024 & 2030
JAPAN
  • Cell Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
  • Table 29: Japan Recent Past, Current & Future Analysis for Cell Therapy by Application - Research and Clinical - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 30: Japan Historic Review for Cell Therapy by Application - Research and Clinical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 31: Japan 16-Year Perspective for Cell Therapy by Application - Percentage Breakdown of Value Sales for Research and Clinical for the Years 2014, 2024 & 2030
  • Table 32: Japan Recent Past, Current & Future Analysis for Cell Therapy by Therapy - Allogenic and Autologous - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 33: Japan Historic Review for Cell Therapy by Therapy - Allogenic and Autologous Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 34: Japan 16-Year Perspective for Cell Therapy by Therapy - Percentage Breakdown of Value Sales for Allogenic and Autologous for the Years 2014, 2024 & 2030
CHINA
  • Cell Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
  • Table 35: China Recent Past, Current & Future Analysis for Cell Therapy by Application - Research and Clinical - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 36: China Historic Review for Cell Therapy by Application - Research and Clinical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 37: China 16-Year Perspective for Cell Therapy by Application - Percentage Breakdown of Value Sales for Research and Clinical for the Years 2014, 2024 & 2030
  • Table 38: China Recent Past, Current & Future Analysis for Cell Therapy by Therapy - Allogenic and Autologous - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 39: China Historic Review for Cell Therapy by Therapy - Allogenic and Autologous Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 40: China 16-Year Perspective for Cell Therapy by Therapy - Percentage Breakdown of Value Sales for Allogenic and Autologous for the Years 2014, 2024 & 2030
EUROPE
  • Cell Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
  • Table 41: Europe Recent Past, Current & Future Analysis for Cell Therapy by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 42: Europe Historic Review for Cell Therapy by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 43: Europe 16-Year Perspective for Cell Therapy by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
  • Table 44: Europe Recent Past, Current & Future Analysis for Cell Therapy by Application - Research and Clinical - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 45: Europe Historic Review for Cell Therapy by Application - Research and Clinical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 46: Europe 16-Year Perspective for Cell Therapy by Application - Percentage Breakdown of Value Sales for Research and Clinical for the Years 2014, 2024 & 2030
  • Table 47: Europe Recent Past, Current & Future Analysis for Cell Therapy by Therapy - Allogenic and Autologous - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 48: Europe Historic Review for Cell Therapy by Therapy - Allogenic and Autologous Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 49: Europe 16-Year Perspective for Cell Therapy by Therapy - Percentage Breakdown of Value Sales for Allogenic and Autologous for the Years 2014, 2024 & 2030
FRANCE
  • Cell Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
  • Table 50: France Recent Past, Current & Future Analysis for Cell Therapy by Application - Research and Clinical - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 51: France Historic Review for Cell Therapy by Application - Research and Clinical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 52: France 16-Year Perspective for Cell Therapy by Application - Percentage Breakdown of Value Sales for Research and Clinical for the Years 2014, 2024 & 2030
  • Table 53: France Recent Past, Current & Future Analysis for Cell Therapy by Therapy - Allogenic and Autologous - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 54: France Historic Review for Cell Therapy by Therapy - Allogenic and Autologous Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 55: France 16-Year Perspective for Cell Therapy by Therapy - Percentage Breakdown of Value Sales for Allogenic and Autologous for the Years 2014, 2024 & 2030
GERMANY
  • Cell Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
  • Table 56: Germany Recent Past, Current & Future Analysis for Cell Therapy by Application - Research and Clinical - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 57: Germany Historic Review for Cell Therapy by Application - Research and Clinical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 58: Germany 16-Year Perspective for Cell Therapy by Application - Percentage Breakdown of Value Sales for Research and Clinical for the Years 2014, 2024 & 2030
  • Table 59: Germany Recent Past, Current & Future Analysis for Cell Therapy by Therapy - Allogenic and Autologous - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 60: Germany Historic Review for Cell Therapy by Therapy - Allogenic and Autologous Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 61: Germany 16-Year Perspective for Cell Therapy by Therapy - Percentage Breakdown of Value Sales for Allogenic and Autologous for the Years 2014, 2024 & 2030
ITALY
  • Table 62: Italy Recent Past, Current & Future Analysis for Cell Therapy by Application - Research and Clinical - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 63: Italy Historic Review for Cell Therapy by Application - Research and Clinical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 64: Italy 16-Year Perspective for Cell Therapy by Application - Percentage Breakdown of Value Sales for Research and Clinical for the Years 2014, 2024 & 2030
  • Table 65: Italy Recent Past, Current & Future Analysis for Cell Therapy by Therapy - Allogenic and Autologous - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 66: Italy Historic Review for Cell Therapy by Therapy - Allogenic and Autologous Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 67: Italy 16-Year Perspective for Cell Therapy by Therapy - Percentage Breakdown of Value Sales for Allogenic and Autologous for the Years 2014, 2024 & 2030
UNITED KINGDOM
  • Cell Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
  • Table 68: UK Recent Past, Current & Future Analysis for Cell Therapy by Application - Research and Clinical - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 69: UK Historic Review for Cell Therapy by Application - Research and Clinical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 70: UK 16-Year Perspective for Cell Therapy by Application - Percentage Breakdown of Value Sales for Research and Clinical for the Years 2014, 2024 & 2030
  • Table 71: UK Recent Past, Current & Future Analysis for Cell Therapy by Therapy - Allogenic and Autologous - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 72: UK Historic Review for Cell Therapy by Therapy - Allogenic and Autologous Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 73: UK 16-Year Perspective for Cell Therapy by Therapy - Percentage Breakdown of Value Sales for Allogenic and Autologous for the Years 2014, 2024 & 2030
REST OF EUROPE
  • Table 74: Rest of Europe Recent Past, Current & Future Analysis for Cell Therapy by Application - Research and Clinical - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 75: Rest of Europe Historic Review for Cell Therapy by Application - Research and Clinical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 76: Rest of Europe 16-Year Perspective for Cell Therapy by Application - Percentage Breakdown of Value Sales for Research and Clinical for the Years 2014, 2024 & 2030
  • Table 77: Rest of Europe Recent Past, Current & Future Analysis for Cell Therapy by Therapy - Allogenic and Autologous - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 78: Rest of Europe Historic Review for Cell Therapy by Therapy - Allogenic and Autologous Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 79: Rest of Europe 16-Year Perspective for Cell Therapy by Therapy - Percentage Breakdown of Value Sales for Allogenic and Autologous for the Years 2014, 2024 & 2030
ASIA-PACIFIC
  • Cell Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
  • Table 80: Asia-Pacific Recent Past, Current & Future Analysis for Cell Therapy by Application - Research and Clinical - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 81: Asia-Pacific Historic Review for Cell Therapy by Application - Research and Clinical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 82: Asia-Pacific 16-Year Perspective for Cell Therapy by Application - Percentage Breakdown of Value Sales for Research and Clinical for the Years 2014, 2024 & 2030
  • Table 83: Asia-Pacific Recent Past, Current & Future Analysis for Cell Therapy by Therapy - Allogenic and Autologous - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 84: Asia-Pacific Historic Review for Cell Therapy by Therapy - Allogenic and Autologous Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 85: Asia-Pacific 16-Year Perspective for Cell Therapy by Therapy - Percentage Breakdown of Value Sales for Allogenic and Autologous for the Years 2014, 2024 & 2030
REST OF WORLD
  • Table 86: Rest of World Recent Past, Current & Future Analysis for Cell Therapy by Application - Research and Clinical - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 87: Rest of World Historic Review for Cell Therapy by Application - Research and Clinical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 88: Rest of World 16-Year Perspective for Cell Therapy by Application - Percentage Breakdown of Value Sales for Research and Clinical for the Years 2014, 2024 & 2030
  • Table 89: Rest of World Recent Past, Current & Future Analysis for Cell Therapy by Therapy - Allogenic and Autologous - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 90: Rest of World Historic Review for Cell Therapy by Therapy - Allogenic and Autologous Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 91: Rest of World 16-Year Perspective for Cell Therapy by Therapy - Percentage Breakdown of Value Sales for Allogenic and Autologous for the Years 2014, 2024 & 2030
IV. COMPETITION

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Anterogen Co., Ltd.
  • Celgene Corporation
  • Cells for Cells S.A. (C4C)
  • Fibrocell Science, Inc.
  • GlaxoSmithKline PLC
  • JCR Pharmaceuticals Co., Ltd.
  • Kolon TissueGene, Inc.
  • Medipost Co., Ltd.
  • Novartis AG
  • NuVasive, Inc.
  • Osiris Therapeutics, Inc.
  • Pharmicell Co., Ltd.
  • Stemedica Cell Technologies, Inc.
  • Vericel Corporation

Table Information